Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Compliance Is Big Business; Software Vendors Offer Trove Of Tools

Executive Summary

These days, the e-mail boxes of pharmaceutical compliance officers are overflowing with offers for help. Consultants and software developers are pitching a variety of wares, from tools that block sales reps from promoting drugs off-label to software that collects aggregate spend on health care providers

You may also be interested in...



Cell Therapeutics Can Sue Consultant For Advice On Off-Label Reimbursement

Two years ago, Cell Therapeutics Inc. doled out $10.6 million to the federal government to resolve allegations it marketed its former leukemia drug Trisenox (arsenic trioxide) for unapproved uses. The company now has a chance to recoup its losses

Health Care Fraud Investigations Bedevil Pharma Industry: If You're Not Under Investigation, It's Only Because You've Recently Settled

Two months ago, the Department of Justice held a splashy news conference to announce its record-breaking $2.3 billion settlement with Pfizer. The event, which included HHS Secretary Kathleen Sebelius, cast a spotlight on Pfizer's alleged off-label marketing and kickbacks to health care providers (1"The Pink Sheet," Sept. 7, 2009)

Cephalon Must Report Payments To Physicians In Settlement Of Off-Label Charges

Cephalon is to become the third pharmaceutical company to disclose its payments to physicians. While Lilly and Merck recently volunteered to do so, Cephalon's disclosure is mandated under a settlement agreement with the U.S. Department of Justice to resolve charges that it promoted off-label use of three drugs

Related Content

Topics

UsernamePublicRestriction

Register

PS051714

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel